Search hospitals > Maryland > Annapolis
Anne Arundel Medical Center
Claim this profileAnnapolis, Maryland 21401
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Recurrence
116 reported clinical trials
14 medical researchers
Summary
Anne Arundel Medical Center is a medical facility located in Annapolis, Maryland. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Anne Arundel Medical Center is involved with conducting 116 clinical trials across 161 conditions. There are 14 research doctors associated with this hospital, such as Adam J. Goldrich, Mary E. Young, Young J. Lee, and Feras Abdul Khalek.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
HER2 positive
2Cancer
Global LeaderStage IV
Stage II
Stage III
Top PIs
Adam J. GoldrichUniversity of Maryland Shore Medical Center at Easton4 years of reported clinical research
Studies Cancer
Studies Breast Cancer
13 reported clinical trials
29 drugs studied
Mary E. YoungAnne Arundel Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Lung Cancer
5 reported clinical trials
11 drugs studied
Young J. LeeAnne Arundel Medical Center1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
5 reported clinical trials
14 drugs studied
Feras Abdul KhalekAnne Arundel Medical Center9 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
3 reported clinical trials
7 drugs studied
Clinical Trials running at Anne Arundel Medical Center
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Cancer
Small Cell Lung Cancer
Prostate Cancer
Squamous Cell Carcinoma
Multiple Myeloma
Prostate Adenocarcinoma
Tumors
Giredestrant + Everolimus
for Advanced or Metastatic Breast Cancer
This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the physician's choice of endocrine therapy plus everolimus in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have had previous treatment with cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) and endocrine therapy, either in the locally advanced/metastatic or the adjuvant setting.
Recruiting2 awards Phase 37 criteria
PF-07220060 + Fulvestrant
for Advanced Breast Cancer
The purpose of this study is to learn about the safety and how effective the study medicine (PF-07220060) plus fulvestrant is compared to the study doctor's choice of treatment in people with advanced or metastatic breast cancer. Advanced cancer is the one that is unlikely to be cured or taken care of with treatment. Metastatic cancer is the one that has spread to other parts of the body. This study is seeking female and male participants who: are 18 years of age or older; are hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative; have advanced or metastatic breast cancer after taking other treatments before this study; have not taken or need to take medications that are not allowed by the study protocol; do not have any medical or mental conditions that may increase the risk of study participation. Half of the participants will take PF-07220060 two times daily by mouth along with fulvestrant. Fulvestrant will be given as a shot into the muscle. The other half will take the study doctor's choice of treatment which can either be: Fulvestrant alone taken as shot into the muscle. Everolimus along with exemestane taken once daily by mouth. This study will compare the experiences of participants receiving the study medicine plus fulvestrant to those who are receiving the study doctor's choice of treatment. This will help decide if the study medicine is safe and effective. Participants will receive study treatment and/or will be in the study until: imaging scans (such as an MRI and/or CT) show that their cancer is getting worse. the study doctor thinks the participant is no longer benefitting from the study medicine. has side effects that become too severe. A side effect is a reaction (expected or unexpected) to a medicine or treatment you take. the participant chooses to stop taking part.
Recruiting2 awards Phase 3
Chemotherapy + Hormone Therapy
for Breast Cancer
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Anne Arundel Medical Center?
Anne Arundel Medical Center is a medical facility located in Annapolis, Maryland. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Recurrence and other specialties. Anne Arundel Medical Center is involved with conducting 116 clinical trials across 161 conditions. There are 14 research doctors associated with this hospital, such as Adam J. Goldrich, Mary E. Young, Young J. Lee, and Feras Abdul Khalek.